IDEXX Laboratories, Inc. $IDXX Position Boosted by Stephens Investment Management Group LLC

Stephens Investment Management Group LLC lifted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 8.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 119,824 shares of the company’s stock after purchasing an additional 9,670 shares during the period. Stephens Investment Management Group LLC owned about 0.15% of IDEXX Laboratories worth $62,571,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in IDXX. Bank of New York Mellon Corp purchased a new position in IDEXX Laboratories in the second quarter valued at $628,223,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of IDEXX Laboratories by 4.6% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 911,489 shares of the company’s stock worth $479,844,000 after acquiring an additional 39,700 shares during the period. Arrowstreet Capital Limited Partnership raised its position in shares of IDEXX Laboratories by 52.4% in the first quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company’s stock worth $471,335,000 after acquiring an additional 288,471 shares during the period. Dimensional Fund Advisors LP raised its position in shares of IDEXX Laboratories by 4.3% in the first quarter. Dimensional Fund Advisors LP now owns 573,332 shares of the company’s stock worth $322,145,000 after acquiring an additional 23,582 shares during the period. Finally, Alyeska Investment Group L.P. boosted its stake in shares of IDEXX Laboratories by 97.3% during the 2nd quarter. Alyeska Investment Group L.P. now owns 401,082 shares of the company’s stock worth $211,146,000 after acquiring an additional 197,808 shares in the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. UBS Group raised their target price on IDEXX Laboratories from $627.00 to $700.00 and gave the company a “neutral” rating in a research report on Tuesday, November 3rd. Morgan Stanley lifted their price target on IDEXX Laboratories from $805.00 to $810.00 and gave the company an “overweight” rating in a research note on Tuesday, November 3rd. JPMorgan Chase & Co. reduced their price target on IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating for the company in a report on Friday, October 16th. Citigroup increased their price target on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 5th. Finally, Barclays dropped their price objective on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. Seven analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $717.27.

Check Out Our Latest Research Report on IDEXX Laboratories

Insider Transactions at IDEXX Laboratories

In related news, insider Jonathan Mazelsky sold 25,140 shares of IDEXX Laboratories stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $703.19, for a total value of $17,678,196.60. Following the sale, the insider directly owned 83,803 shares in the company, valued at approximately $58,929,431.57. The trade was a 23.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Daniel M. Junius sold 1,200 shares of the business’s stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $704.07, for a total value of $844,884.00. Following the sale, the director owned 2,361 shares of the company’s stock, valued at approximately $1,662,309.27. This trade represents a 33.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 41,428 shares of company stock worth $28,567,934 in the last three months. 0.79% of the stock is owned by corporate insiders.

IDEXX Laboratories Stock Performance

IDXX opened at $698.47 on Thursday. The company has a quick ratio of 0.88, a current ratio of 1.19 and a debt-to-equity ratio of 0.16. The company has a market cap of $55.03 billion, a price-to-earnings ratio of 47.10 and a beta of 1.55. IDEXX Laboratories, Inc. has a 52-week low of $500.61 and a 52-week high of $769.98. The firm’s fifty day simple moving average is $572.78 and its two-hundred day simple moving average is $573.79.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last announced its earnings results on Monday, November 2nd. The company reported $3.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.71 by $0.25. The business had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.19 billion. IDEXX Laboratories had a net margin of 25.36% and a return on equity of 71.04%. The company’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same quarter last year, the business earned $3.22 earnings per share. Equities analysts anticipate that IDEXX Laboratories, Inc. will post 15.05 earnings per share for the current fiscal year.

About IDEXX Laboratories

(Free Report)

IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices. The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality.

Featured Articles

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.